Immunotherapy News and Research

Latest Immunotherapy News and Research

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Bone marrow transplantation is a life-saving therapy for patients with blood cancers like leukemia or lymphoma. However, the depletion of the patient's immune system prior to transplantation can put patients at risk of for an infection by a virus called cytomegalovirus (CMV) that can be life threatening in these immune-compromised individuals.

4 Feb 2015

Experts recommend sublingual immunotherapy for treatment of allergic rhinitis

Sublingual immunotherapy is one of several state-of-the-science treatments for allergic rhinitis, or "hay fever," being recommended by a panel of experts in a new guideline published Feb. 2, 2015, by the American Academy of Otolaryngology--Head and Neck Surgery Foundation.

3 Feb 2015

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

The University of Texas MD Anderson Cancer Center and AstraZeneca today announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

31 Jan 2015

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

A mosquito-borne virus that has spread to the Caribbean and Central and South America and has caused isolated infections in Florida often causes joint pain and swelling similar to that seen in patients with rheumatoid arthritis.

31 Jan 2015

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA).

30 Jan 2015

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

With President Obama's recent State of the Union speech addressing the launch of a national precision medicine initiative to further tackle cancer and other diseases, a leading immunotherapy expert from Rutgers Cancer Institute of New Jersey weighs in on where we stand with precision immunology and personalized medicine and what needs to be accomplished.

30 Jan 2015

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients.

28 Jan 2015

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

27 Jan 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States.

23 Jan 2015

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

The American Association of Immunologists has selected Professor Jonathan Sprent FAA FRS, from Sydney's Garvan Institute of Medical Research, to be the 2015 recipient of the AAI Lifetime Achievement Award.

23 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

New experimental study shows immunotherapy can reduce acute effects of heroin

Immunotherapy could have a place in the treatment of substance abuse in the future. A specific antibody can reduce the acute effects of heroin, according to a new experimental study at the Norwegian Institute of Public Health.

21 Jan 2015

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.

20 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Tübingen researchers develop new way of labeling T-cells

To better understand what happens during immune reactions in the body, researchers at Tübingen University have developed a new way of labeling T-cells, allowing them to track the T-cell movement in mice using non-invasive positron emission technology (PET).

19 Jan 2015

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015.

15 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

The study carried out by researchers from the Centre for Plant Biotechnology and Genomics along with the Allergy Department of the Hospital Infantil Universitario Niño Jesús of Madrid have shown that, most of the children that received this new oral immunotherapy treatment were able to eat 100 grams of wheat bread without side effects. This result has overcome the risk of accidental ingestion by patients with this allergy. This research could be the basis for large clinical trials with more patients with the aim of assessing the therapeutic benefit of this new approach.

13 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Experts recommend sublingual immunotherapy for treatment of allergic rhinitis

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

NCCS launches human clinical trial of new cancer vaccine

New experimental study shows immunotherapy can reduce acute effects of heroin

ASCO announces cancer Advance of the Year

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Tübingen researchers develop new way of labeling T-cells

CAR T-cell therapy enters into Phase I clinical trial

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

TxCell announces further enhancement to development of Ovasave for IBD treatment

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in